A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy
Public ClinicalTrials.gov record NCT06568237. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to evaluate the efficacy of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the study is to evaluate specific efficacy parameters of TEV-56286. Another secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned study period per participant is 56 weeks including a screening period (up to 4 weeks), a 48-week double-blind treatment period, and a follow-up visit (approximately 4 weeks after the end of the double-blind treatment period). The study duration will be approximately 27 months.
Study identification
- NCT ID
- NCT06568237
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 350 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 1, 2024
- Primary completion
- Sep 14, 2027
- Completion
- Sep 14, 2027
- Last update posted
- Jul 19, 2026
2024 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 15
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 15554 | La Jolla | California | 92037 | Recruiting |
| Teva Investigational Site 15545 | Los Angeles | California | 90095 | Not yet recruiting |
| Teva Investigational Site 15547 | Washington D.C. | District of Columbia | 20007 | Recruiting |
| Teva Investigational Site 15544 | Boca Raton | Florida | 33486 | Active, not recruiting |
| Teva Investigational Site 15555 | Tampa | Florida | 33613 | Recruiting |
| Teva Investigational Site 15550 | Chicago | Illinois | 60612-3852 | Recruiting |
| Teva Investigational Site 15546 | Kansas City | Kansas | 66160 | Recruiting |
| Teva Investigational Site 15736 | Boston | Massachusetts | 02115 | Recruiting |
| Teva Investigational Site 15870 | Farmington Hills | Michigan | 48334 | Not yet recruiting |
| Teva Investigational Site 15552 | Rochester | Minnesota | 55905 | Recruiting |
| Teva Investigational Site 15549 | New York | New York | 10016 | Recruiting |
| Teva Investigational Site 15551 | New York | New York | 10032-3726 | Recruiting |
| Teva Investigational Site 15553 | Durham | North Carolina | 27705-4410 | Active, not recruiting |
| Teva Investigational Site 15735 | Hershey | Pennsylvania | 17033 | Not yet recruiting |
| Teva Investigational Site 15548 | Pittsburgh | Pennsylvania | 15213 | Recruiting |
| Teva Investigational Site 15874 | Nashville | Tennessee | 37212 | Recruiting |
| Teva Investigational Site 15869 | Georgetown | Texas | 78628 | Not yet recruiting |
| Teva Investigational Site 15873 | Alexandria | Virginia | 22310 | Active, not recruiting |
| Teva Investigational Site 15543 | Spokane | Washington | 99202 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06568237, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 19, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06568237 live on ClinicalTrials.gov.